Researchers make groundbreaking discovery that solves pressing challenges for urban agriculture: 'Transformative potential'
A solar-powered smart irrigation system is helping urban farmers grow more food with less water and energy. The innovative system reduced water consumption by over 28% compared to conventional irrigation methods, according to a study in the journal Scientific Reports. It reduced energy use by about the same amount.
This technology tackles several pressing challenges at once: water scarcity, energy costs, and the need for sustainable urban agriculture.
Using real-time soil moisture monitoring and solar power, the system delivers precisely the right amount of water only when plants need it, making rooftop gardening more resource-efficient.
Researchers from Egypt's Ain Shams University designed and tested the system over about a year using peppermint plants grown in rooftop gardens. Their smart irrigation setup incorporated sensors that continuously monitor soil moisture, activating water pumps only when levels drop below a certain threshold, then shutting off once optimal moisture is reached.
The smart system reduced energy consumption by the same 28.1% margin and cut carbon pollution from 0.252 kilograms of carbon dioxide emitted per square meter of land per year to just 0.181 kilograms.
"This study underscores the transformative potential of solar-powered smart irrigation systems in enhancing food security, conserving water, reducing energy consumption, and mitigating carbon emissions in urban agriculture," the researchers noted in their paper.
This innovation addresses the "water-energy-food nexus," the intricate relationship between these three important resources. Urban areas struggle with this nexus, which manifests as limited green spaces, water scarcity, and pollution. This irrigation system is a strong solution, as it turns unused rooftops into productive garden spaces.
For small farmers, the possible economic benefits are immense. The system could pay for itself in 5.6 years through water and energy savings. With this technology, people could enjoy fresher food, lower utility bills, and the satisfaction of having a reduced environmental impact.
This innovation could be particularly valuable as cities grow, with urban populations projected to increase to 68% of the global total by 2050. Using rooftop spaces for efficient food production would create urban self-sufficiency and cooler city environments.
The system is already working in real-world conditions and could be widely available quickly, depending on how manufacturing is scaled up. With similar technologies already entering the market, you might soon have access to affordable smart irrigation for your garden, helping you grow food sustainably while conserving precious resources.
What's the biggest factor stopping you from investing in solar panels?
The cost
The technology
I'm a renter
I'm already invested
Click your choice to see results and speak your mind.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
5 hours ago
- Gizmodo
A Monkey Herpesvirus Could Hold Key to New Cancer Treatment
A cousin of herpes might just help us fight cancer. Scientists have engineered a protein derived from a herpesvirus in monkeys that could enhance the immune system's potency against cancer. Researchers at the University of Michigan detailed their work on the protein in a paper published last month. In experiments with mice, the protein prolonged the life of cancer-fighting T cells, leading to reduced tumor growth. The findings point to a novel way that we can further strengthen immune-related cancer treatments, the researchers say. The protein comes from herpesvirus saimiri, named after the squirrel monkeys (all members of the genus Saimiri) that the virus primarily infects. The researchers had identified the virus as carrying proteins that activate certain pathways in T cells—the immune system's frontline soldiers against infections and cancers—that extended their survivability. They ultimately engineered a modified version of one particular protein from the virus, called tyrosine kinase interacting protein (TIP). They hoped their version of TIP could bind to a protein in T cells that would stimulate the production of other proteins called STAT that could then boost the T cells' longevity and cancer-killing potential. As expected, the protein increased levels of STAT (specifically the protein STAT5) in T cells in a Petri dish. They then tested the protein on mice with melanoma and lymphoma. The T cells of treated mice lived longer and killed tumor cells more effectively, resulting in reduced cancer growth, the researchers found. 'Our findings demonstrate that signaling pathways can be rewired in T cells to sustain their function in solid tumors,' the researchers wrote in the paper, published in Science Immunology. In recent years, scientists have developed a class of treatments that ramp up the immune system's natural ability to recognize and attack cancers, which is broadly known as immunotherapy. So the U-M scientists believe that their protein could be used in combination with existing immunotherapies to keep T cells in tip-top cancer-bashing shape. More broadly, they believe that other organisms or their genes can be tweaked to modify our immune cells to make them better at fighting cancers. The team's protein is still experimental, so it will take plenty more research to know whether it can be safely and effectively used in people. But it may not take too long for other herpesviruses to contribute to cancer treatment. Several research teams have developed modified versions of the herpes simplex 1 virus (the primary cause of cold sores) to directly eradicate tumors. Some of these treatments have already begun to be tested in people, and have shown promise in early clinical trials so far.
Forbes
8 hours ago
- Forbes
Gene Therapy For Inherited Disease In The Unborn Child
Until recently, even the most advanced gene therapies could only be given after a child was ... More born—often racing against time to prevent irreversible damage. In the first part of this series, we explored how early genetic screening and gene therapy transform the lives of newborns and their families. Now, we're taking an even earlier step: treating inherited diseases in the womb before birth. Until recently, even the most advanced gene therapies could only be given after a child was born—often racing against time to prevent irreversible damage. But what if we could intervene even earlier? That's the question now being answered, with some astonishing results. A recent study published in Science Translational Medicine showed that delivering a special kind of genetic therapy directly to the fetus could prevent the onset of spinal muscular atrophy in animal models. Treating the condition before birth may be possible to preserve healthy motor function and prevent the nerve damage that usually begins in the womb. This is the first time we see molecular therapies targeting the root cause of inherited disease before birth. Another special investigational case, the first in humans, found that providing the mother with gene therapy while pregnant and continuing treatment after birth also prevented the devastating muscle weakness that usually comes with the disease. This is a true leap forward: instead of managing symptoms; we may soon be able to stop some inherited diseases before they ever begin. The journey starts with advanced prenatal genetic screening. Genetic changes in the developing fetus can be found using a simple blood sample from the mother. When a risk is found, therapy is delivered directly to the fetus, often by injecting medicine into the amniotic fluid. In the case of spinal muscular atrophy, this approach in animal models led to healthier development and longer survival. These findings suggest that intervening before birth can prevent or significantly reduce the neurological damage that begins in the womb and progresses rapidly after birth. While most of this research has been in animals, the first human steps have already begun. In February 2025, the University of California, San Francisco, reported the world's first attempt to treat a genetic disease in a human fetus using a medication called risdiplam. After learning that her unborn child was at risk, a mother began taking the medication late in pregnancy. The baby was born healthy and—now more than two years old—shows no signs of the disease, though some developmental challenges remain. Another important step was taken in a clinical trial at UCSF, where doctors successfully treated a fetus with a different rare disease using enzyme replacement therapy, showing that the technology for delivering medicine to the unborn is already here. Many inherited diseases cause the most significant harm before a baby is even born. By intervening early, we have the chance to save lives and give children the best possible start—preserving their ability to move, think, and grow. This isn't just a medical advance. It's a new way of thinking about what's possible for families facing genetic disease. Of course, there are still challenges ahead. Many are working to ensure these therapies are safe, effective, and accessible to all who need them. Ethical questions about when and how to use these powerful tools will also need careful thought. The first human applications of gene therapy before birth are expected within the next decade, pending rigorous safety and ethical evaluations. This new era also brings new questions. If we correct a genetic error in a child before birth, will that change be passed on to future generations? For now, most therapies target the body's somatic cells, not the germline, so the changes are not inherited. However, the line between somatic and germline interventions may blur as technology evolves, raising complex ethical considerations. The first human trials of in-utero gene therapy are just beginning, and more research is needed. But the direction is clear: as technology advances, we are moving from treating inherited diseases after birth to preventing them at the start of life. As I have often said, the future of medicine is being rewritten, one gene at a time. This latest breakthrough brings us one step closer to a world where prevention, rather than treatment, becomes the standard for genetic disease, where every child can live their healthiest life from the very start. As discussed in my book, the hope is that every child will soon have the chance to live their healthiest life from the beginning.
CNN
11 hours ago
- CNN
Gene mutation found in the bacterium behind the Black Death helped plague conquer the world, scientists say
One of the bleakest periods in medieval Europe was the plague pandemic known as the Black Death, which killed at least 25 million people in just five years. But the disease didn't stop there. The plague adapted to keep its hosts alive longer, so it could spread farther and keep infecting people for centuries, and researchers now say they've discovered how. The disease is caused by the bacterium Yersinia pestis, which has been circulating among human populations for at least 5,000 years. The pathogen has fueled three major plague pandemics since the first century AD, and though its deadliest years appear to be behind us, plague hasn't disappeared. Cases still occur a few times a year in Asia, South America and the United States and more commonly in parts of Africa, according to the Cleveland Clinic, and can be treated with antibiotics. Scientists are still searching for answers about how Y. pestis evolved and dispersed, but recent analysis of ancient and modern Y. pestis samples revealed how plague managed to persist among humans for hundreds of years after pandemic waves petered out. After an initial period of high infection rates and rapid mortality — killing infected people within three days — changes to just one gene in the bacterium produced new strains that were less deadly and more transmissible, according to research published Thursday in the journal Science. Those weakened strains eventually went extinct; the dominant lineage of today's Y. pestis is the deadlier variety, the study authors reported. However, these findings about historic instances of Y. pestis adaptation could provide important clues to help scientists and physicians manage modern plague outbreaks. Plague's most common form is bubonic plague, which causes painful swelling in lymph nodes and spreads among people through bites from fleas hitchhiking on infected rats. An outbreak of bubonic plague from 1347 to 1352 in Europe famously killed about 30% to 50% of the continent's population. But the earliest known bubonic plague outbreak — the Plague of Justinian — took hold in the Mediterranean Basin and lasted from AD 541 to AD 544. Another plague outbreak emerged in China in the 1850s and sparked a major epidemic in 1894. Scientists view modern plague cases as part of this third pandemic. For the new study, scientists collected ancient samples of Y. pestis from human remains dating back to about 100 years after the appearance of the first and second plague pandemics, sampling remains from Denmark, Europe and Russia. After reconstructing the genomes of these plague strains, they compared them with older, ancient strains that dated back to the start of plague pandemics. The researchers also examined more than 2,700 genomes of modern plague samples from Asia, Africa, and North and South America. One of the study coauthors, Jennifer Klunk, is a product scientist at Daciel Arbor Biosciences, a biotechnology company in Michigan that provided synthetically created molecules for the experiments, but there was no financial gain associated with the research. The researchers found that their newly reconstructed genomes from 100 years into the first two plague pandemics had fewer copies of a gene called pla, which has been recognized for decades as one of the factors that made plague so deadly, according to the study's co-lead author Ravneet Sidhu, a doctoral student in the McMaster Ancient DNA Centre at McMaster University in Ontario, Canada. Pla encodes an enzyme that interacts with host proteins, 'and one of the functions that it carries out is in breaking down blood clots,' Sidhu told CNN. This ability helps Y. pestis spread into the host's lymph nodes, where it replicates before attacking the rest of the body. 'Not every function of this gene is fully known,' Sidhu added. However, prior studies by other researchers linked pla to severity of illness caused by both bubonic and pneumonic plague — an airborne form of the disease that affects the lungs, she said. While the reconstructed strains showed fewer copies of the pla gene, the scientists were still uncertain whether that would directly affect how deadly the disease could be. So they tested strains of reduced-pla bubonic plague on mice, and found that survival rates for this type of plague were 10 to 20 percent higher in those experiment subjects than in mice infected with Y. pestis that had a normal amount of the pla gene. It also took the reconstructed bubonic strain about two days longer to kill its hosts. 'The paper presents a strong argument that depletion, but not total loss, of Pla (the enzyme produced by the pla gene) is part of the evolution of the plague pathogen and may help explain the decline of plague in the second pandemic commonly known as the Black Death,' said Dr. Deborah Anderson, a professor of veterinary pathobiology at the University of Missouri's College of Veterinary Medicine. Anderson, who was not involved in the new research, investigates the virulence of plague, and these findings could shed light on transmission patterns in modern cases, she told CNN in an email. 'Our laboratory studies the flea-rodent cycle and we have collaborators who conduct field research in areas that experience annual or occasional plague outbreaks in the wild,' Anderson said. 'There are nearly 300 rodent species that can transmit Yersinia pestis, and today, burrowing rodents such as prairie dogs or ground squirrels are considered key animal hosts that experience outbreaks of disease,' she added. 'After reading this paper, we will pay closer attention to Pla in the future to see if there continues to be a role for its expression in driving the explosive outbreaks of plague in the animal populations.' Mathematical models suggested how this might have played out in human populations centuries ago, leading to an 'epidemic burnout' about 100 years after a bubonic plague outbreak. In a pandemic's early stages, infections were swift, and death came quickly for both rats and humans. Over time, as dense rat populations thinned out, selective pressures favored the emergence of a less deadly strain of Y. pestis, with fewer copies of the pla gene. Rat hosts infected with this new strain would have a little more time to carry the disease, potentially enabling them to infect more rats — and more people. 'They suggest a model that can be readily pursued in the laboratory that may help explain the spread of plague today in the wild,' Anderson said. These weaker strains of the disease eventually sputtered out and went extinct. In the modern samples, the researchers found just three examples of strains with reduced pla genes, from Vietnam: one from a human subject and two from black rats (Rattus rattus). 'We've been able to do this really cool interdisciplinary study between the modern and ancient data and marry these things that have been happening throughout (the plague's) long evolutionary history,' Sidhu said. 'It could be interesting to see how future researchers continue to try and bridge that gap between the modern third pandemic and those first and second ancient pandemics, to see other similarities. Because there aren't a lot of ancient pathogens that we have as much data on, as we do for Yersinia pestis.' One of the unusual features of plague pandemics is their persistence, and understanding how Y. pestis changed its infection patterns and survived over time could shed light on the adaptive patterns of modern pandemics such as Covid-19, she added. 'Even if we aren't experiencing it to the amount that we were in 2020 or 2021, the pathogen is in the background — still evolving and persisting.' Mindy Weisberger is a science writer and media producer whose work has appeared in Live Science, Scientific American and How It Works magazine. She is the author of 'Rise of the Zombie Bugs: The Surprising Science of Parasitic Mind Control' (Hopkins Press).
